Literature DB >> 2785470

Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.

G J Gores1, R H Wiesner, E R Dickson, A R Zinsmeister, R A Jorgensen, A Langworthy.   

Abstract

The aims of our prospective study were to determine the development and natural history of esophageal varices and variceal bleeding in patients with primary biliary cirrhosis. As part of a controlled clinical study, 265 patients with primary biliary cirrhosis who did not have esophageal varices at entry were followed for a median of 5.6 yr. The mean age was 49 yr (range 26-75 yr), 89% were women, and 69% had advanced histologic stage disease (stage 3-4) on liver biopsy at study entry. All patients were screened annually for esophageal varices by barium esophogram or endoscopy, or both; endoscopy was used to diagnose all episodes of esophageal variceal bleeding. Esophageal varices developed in 83 (31%) patients, and 40 (48%) of those with esophageal varices experienced one or more episodes of esophageal variceal bleeding. Cox regression analysis indicated that only serum bilirubin and histologic stage were associated independently with time to development of esophageal varices. In patients who developed esophageal varices, 33% and 41% developed esophageal variceal bleeding at 1 and 3 yr, respectively. After development of esophageal varices, 1- and 3-yr survival estimates were 83% and 59%, respectively. After the initial variceal bleeding episode, survival estimates were 65% and 46% at 1 and 3 yr and were dependent on Child's classification. These findings are important in considering indications for prophylactic therapy for esophageal varices in primary biliary cirrhosis and may influence timing of liver transplantation.

Entities:  

Mesh:

Year:  1989        PMID: 2785470     DOI: 10.1016/0016-5085(89)90526-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  29 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey.

Authors:  Justin Cheung; Winnie Wong; Iman Zandieh; Yvette Leung; Samuel S Lee; Alnoor Ramji; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

3.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

4.  Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices.

Authors:  Yosuke Murata; Masanori Abe; Shinya Furukawa; Teru Kumagi; Hidetaka Matsui; Kana Matsuura; Bunzo Matsuura; Yoichi Hiasa; Morikazu Onji
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

5.  Meta-analysis of capsule endoscopy in patients diagnosed or suspected with esophageal varices.

Authors:  Yi Lu; Rui Gao; Zhuan Liao; Liang-Hao Hu; Zhao-Shen Li
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

6.  Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?

Authors:  B Bressler; R Pinto; D El-Ashry; E J Heathcote
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 7.  Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage.

Authors:  Romaric Loffroy; Louis Estivalet; Violaine Cherblanc; Sylvain Favelier; Pierre Pottecher; Samia Hamza; Anne Minello; Patrick Hillon; Pierre Thouant; Pierre-Henri Lefevre; Denis Krausé; Jean-Pierre Cercueil
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 8.  Modern management of oesophageal varices.

Authors:  P J Gow; R W Chapman
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

Review 9.  Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review.

Authors:  Eleonora Tamborini Permunian; Lorenzo Gervaso; Victor Gerdes; Lorenzo Moja; Luigina Guasti; Alessandro Squizzato
Journal:  Intern Emerg Med       Date:  2018-04-02       Impact factor: 3.397

10.  MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Authors:  Tomohiro Katsumi; Masashi Ninomiya; Taketo Nishina; Kei Mizuno; Kyoko Tomita; Hiroaki Haga; Kazuo Okumoto; Takafumi Saito; Tooru Shimosegawa; Yoshiyuki Ueno
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.